The newly emerged Nashville Biosciences has the considerable genomics and bioinformatics resources of Vanderbilt behind it as it promotes new R&D techniques.
The startup aims to tap into the $60 billion probiotics industry by sequencing the microbiomes of athletes to identify bacteria that improve performance.
Researchers from the Netherlands Cancer Institute plan to spin out a company to use sequencing-based cellular network mapping to aid in drug development.
Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
